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Abstract
Aims/hypothesis Plasma kallikrein is the central mediator of the plasma kallikrein–kinin system, which is involved both in vascular
control and thrombin formation cascades. The plasma kallikrein–kinin system has also been considered protective in pathological
conditions, but the impact of plasma kallikreins on diabetic nephropathy remains unknown. The objective of this cross-sectional study
was to explore the association of plasma kallikrein with diabetic nephropathy.
Methods We measured plasma kallikrein activity in 295 individuals with type 1 diabetes at various stages of diabetic nephrop-
athy, and we tested the genetic association between the plasma kallikrein–kinin system and kidney function in 4400 individuals
with type 1 diabetes.
Results Plasma kallikrein activity was associated with diabetes duration (p < 0.001) and eGFR (p < 0.001), and plasma kallikrein
activity was lower with more advanced diabetic nephropathy, being lowest in individuals on dialysis. The minor alleles of the
KNG1 rs5030062 and rs710446 variants, which have previously been associated with increased plasma pre-kallikrein and/or
factor XI (FXI) protein levels, were associated with higher eGFR (rs5030062β = 0.03, p = 0.01; rs710446β = 0.03, p = 0.005) in
the FinnDiane cohort of 4400 individuals with type 1 diabetes.
Conclusions/interpretation Plasma kallikrein activity and genetic variants known to increase the plasma kallikrein level are
associated with higher eGFR in individuals with type 1 diabetes, suggesting that plasma kallikrein might have a protective effect
in diabetic nephropathy.
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Abbreviations
ESRD End-stage renal disease
FXI Factor XI
FXII Factor XII
FinnDiane Finnish Diabetic Nephropathy Study
HMWK High-molecular-weight kininogen
KKS Kallikrein–kinin system
RAAS Renin–angiotensin–aldosterone system
Introduction
Finland has the highest incidence of type 1 diabetes in the
world [1]. One-third of these individuals with type 1 diabetes
are at high risk of the devastating complication diabetic
nephropathy, which is associated with a manifold increased
risk of cardiovascular disease and premature death. The path-
ogenesis of diabetic nephropathy is still not fully understood,
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but chronic inflammation, endothelial dysfunction and genetic
propensity seem to play a role.
The kallikrein–kinin system (KKS) is considered part
of the vasodilation regulatory system and is also involved
in endothelial NO stimulation. Plasma kallikrein (encoded
by the gene kallikrein B1[KLKB1]) has kininogenase
activity through high-molecular-weight kininogen
(HMWK) and it circulates in the blood as an inactive
pre-kallikrein, bound to its cofactor HMWK. Cleavage
of the kallikrein–HMWK complex leads to the release of
the vasoactive peptide bradykinin, thus affecting vasodi-
lation and inflammation, but, more importantly, it leads to
increased NO release and bioavailability [2] and fibrin
degradation [3], functions that may potentially be
vasoprotective. Although it is widely accepted that the
plasma KKS, as part of the contact-activated cascade, is
locally assembled and profoundly silenced by various
plasma inhibitors, accumulating evidence indicates that
plasma KKS is activated by contact with an activated
endothelial surface [4–7]. As kidneys have one of the
most diverse endothelial cell populations amongst organs
and some of the hallmarks of kidney disease are endothe-
lial dysfunction and reduced NO synthesis and bioavail-
ability, we aimed to evaluate plasma kallikrein activity in
individuals with type 1 diabetes and diabetic nephropathy.
We screened for previously published functional genetic
variants that are known to affect the plasma KKS to
assess their effect on kidney function in individuals with
type 1 diabetes.
Methods
Participants The nationwide Finnish Diabetic Nephropathy
Study (FinnDiane) aims to identify genetic, environmental and
clinical risk factors for diabetic complications such as diabetic
nephropathy in adult individuals with type 1 diabetes. The study
protocol was approved by the ethics committee of the Helsinki
and Uusimaa Hospital District, and each participant gave written
informed consent before the study. During the study visit, blood
pressure was measured, blood samples (fasting or after a light
breakfast) were collected and analysed for HbA1c and serum
creatinine by accredited hospital laboratory methods at the
Helsinki University Central Hospital Laboratory (HUSLAB;
www.hus.fi) or at the local study centres. eGFR was calculated
using the Chronic Kidney Disease–Epidemiology Collaboration
(CKD-EPI) equation and renal status was assessed using urinary
albumin excretion rate and albumin/creatinine ratio. For details
regarding diagnostic criteria and clinical assessments please refer
to the Electronic supplementary material (ESM) Methods.
Samples and storage For this cross-sectional sub-study, plasma
sample collection commenced in the year 2012, and all individ-
uals visiting at the Helsinki University Hospital FinnDiane centre
during 2012–2016 were included. Plasma citrate samples were
collected from each participant into a 3 ml vacutainer containing
0.109mol/l sodium citrate. Tominimise protease auto-activation,
samples were incubated for 30 min and then centrifuged at room
temperature for 15 min at 2000 g. Plasma was collected and
centrifuged again for 15min at 2000 g. The final plasma samples
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were divided into 1 ml polystyrene tubes and stored at −80°C
until analysis.
Plasma kallikrein assay The plasma kallikrein assay was done
using a chromogenic substrate H-D-Pro-Phe-Arg-
paranitroanilide (S-2302, Haemochrom Diagnostica, Essen,
Germany). For a detailed description of the assay protocol
and validation, please refer to the ESM Methods.
Factor XI assay We assessed factor XI (FXI) activity together
with plasma kallikrein since the upstream coagulation factor
factor XII (FXII) activates FXI in parallel with plasma kalli-
krein (ESM Fig. 1). The FXI assay was performed using a
chromogenic substrate-based commercial assay (product no.
COA0090; CoaChrom Factor XI, Coachrom Diagnostica,
Maria Enzersdorf, Austria). For detailed information about
the assay, please refer to the ESM methods.
Genotyping and quality control All available DNA samples
(stored at −20°C) for the FinnDiane cohort underwent
genome-wide genotyping using Illumina HumanCoreExome
BeadChips (Illumina, San Diego, CA, USA) at the Genome
Analysis and Technology Core (University of Virginia,
Charlottesville, VA, USA) in 2016. After quality control, data
on eGFR were available for 4400 of the participants eligible
for this study, which included 294 individuals with measured
plasma kallikrein activity. For details on the genotyping and
quality control, please refer to the ESM Methods.
SNP selection We selected five previously identified SNPs
(ESM Table 1) with established genome-wide significant
associations with circulating FXII (F12 rs1801020), plasma
pre-kallikrein (KLKB1 rs1511802, KNG1 rs5030062) or FXI
(KNG1 rs5030062, KNG1 rs710446, F11 rs4253417, F11
rs6842047, F11 rs2289252) levels/activity. For details regard-
ing the SNP selection criteria and characteristics, see ESM
Methods and ESM Table 2.
Statistical analyses Plasma kallikrein values transformed using
the natural logarithm for regression analyses. Multiple-group
comparisons were performed using non-transformed data and
the Kruskal–Wallis test, and two-group comparisons were
performed using the Mann–Whitney U test. Spearman’s rank
correlation and Pearson’s correlation were used for non-
parametric and parametric data correlations, respectively.
Logistic and linear regression analyses were used to test asso-
ciations between individual SNPs and categorical and continu-
ous variables, respectively. A p value <0.05 was considered
statistically significant. For statistical methods for genetic anal-
yses and power analyses, please refer to the ESM Methods.
Results
Participant characteristics In the study cohort of 295 individ-
uals with measured plasma kallikrein and FXI activity, 163
weremen (55.3%). Themean (±SD) age was 47.2 ± 12.5 years
and the mean duration of diabetes was 30.2 ± 11.9 years. The
study cohort was divided into normoalbuminuria (n = 165),
microalbuminuria (n = 41), macroalbuminuria (n = 37) and
end-stage renal disease (ESRD, n = 52) (for category
thresholds, see ESMMethods, Participants). For more details,
see ESM Results and ESM Table 3.
Impact of age, diabetes duration and medication on plasma
kallikrein activity In individuals with normoalbuminuria, both
plasma kallikrein and FXI activity correlated negatively with
age (r = −0.29, p < 0.001 and r = −0.21, p = 0.006, respective-
ly), but only plasma kallikrein activity correlated negatively
with diabetes duration (r = −0.27, p < 0.001).
Because the renin–angiotensin–aldosterone system
(RAAS) and plasma KKS are interconnected systems, several
antihypertensive medications could impact plasma kallikrein
activity. In line with this, we observed an association between
plasma kallikrein activity and RAAS-blocker therapy (β =
−0.32, p = 0.03, see ESM Results for further details).
RAAS-blocker therapy was thus accounted for in further
regression analyses.
Fig. 1 (a) Plasma kallikrein activity decreases by advancing stage of
diabetic nephropathy in individuals with type 1 diabetes.
Normoa lbuminu r i a , n = 165 ; mic roa lbuminu r i a , n = 41 ;
macroalbuminuria, n = 37; ESRD, n = 52. (b) Plasma kallikrein activity
in individuals with ESRD. Individuals on dialysis, n = 16; individuals
with a kidney transplant, n = 36. Plasma kallikrein activity is expressed
as fold change vs healthy control plasma samples. Box plots represent
median, interquartile range and upper and lower quartile of plasma kalli-
krein activity levels. In (b), the grey circles represent individual data
points, the black dots represent outliers. *p < 0.05, **p < 0.01,
***p < 0.001
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Plasma kallikrein and FXI activity in individuals with diabetic
nephropathy Plasma kallikrein activity decreased with more
advanced stages of diabetic nephropathy: normoalbuminuria
(median 2.53, [IQR 1.37–4.23]; n = 165), microalbuminuria
(2.04 [1.23–3.40]; n = 41), macroalbuminuria (1.31 [0.91–
2.81]; n = 37), and ESRD (1.23 [0.66–1.72]; n = 52;
p < 0.001) (Fig. 1a). Plasma kallikrein activity correlated posi-
tively with eGFR (r = 0.34; p < 0.001). This association
remained after adjustment for age, sex, diabetes duration,
waist circumference, HbA1c and RAAS-blocker therapy
(β = 0.24 [95% CI 0.14, 0.34], p < 0.001). Within the ESRD
group, plasma kallikrein activity was lower in individuals on
dialysis (median 0.74, [IQR 0.55–1.41], n = 16) than in kidney
transplant recipients (1.51 [0.96–1.95]; p = 0.008, n = 36)
(Fig. 1b). FXI activity did not differ within the ESRD group
and was not associated with eGFR (data not shown).
Plasma kallikrein and genetic variants Genetic associations
(adjusted for age, sex and diabetes duration) between selected
SNPs and kallikrein activity were confirmed in the primary
study cohort of 295 individuals. Altogether, three SNPs
(KNG1 rs5030062, rs710446 and F12 rs1801020) were asso-
ciated with plasma kallikrein activity (Table 1, ESM Results
and ESM Fig. 2a, b) and selected for further analyses in the
larger cohort of 4400 individuals (adjusted for age, sex, diabetes
duration, RAAS-blocker therapy and the two first principal
components). In these analyses, the minor allele of KNG1
rs5030062 and rs710446were additively associatedwith higher
eGFR (rs5030062 β = 0.03, p = 0.01; rs710446 β = 0.03, p =
0.005). The association remained after removing individuals
who had received kidney transplants ([n = 271] rs5030062
β = 0.02, p = 0.05; rs710446 β = 0.03, p = 0.01) and after
removing first-degree relatives ([n = 182] rs5030062 β = 0.03,
p = 0.02; rs710446β = 0.03, p = 0.01). For expanded results on
the associations between kallikrein and genetic variants and for
results on the genetic associations with blood pressure and 24 h
urine sodium, please refer to the ESM results.
Discussion
In this study we investigated the association of plasma kallikrein
with kidney function and diabetic nephropathy in 295 individuals
with type 1 diabetes. We showed that plasma kallikrein activity
was associated with diabetes duration and eGFR and that the
activity was lower in more advanced diabetic nephropathy, being
lowest in individuals on dialysis. Furthermore, the minor alleles
of the KNG1 rs5030062 and rs710446 variants, which are asso-
ciated with increased plasma pre-kallikrein and/or FXI levels,
were associated with higher eGFR in the FinnDiane cohort of
4400 individuals with type 1 diabetes.
Irregularities in plasma KKS homeostasis have been
demonstrated in individuals with type 1 diabetes and diabetic
nephropathy [8–10], but the reason behind the decline in plas-
ma kallikrein activity in our study is unknown. As plasma
kallikrein circulates in complex with HMW-kininogen
(280 kDa), it is unlikely to be filtered out when bound to its
cofactor. However, when the plasma kallikrein–HMW-kinin-
ogen complex is cleaved, e.g. in response to damaged endo-
thelium, then active plasma kallikrein (89 kDa) could be
excreted in the urine [11], as the damage to the glomerular
basement membrane increases. This could potentially result in
reduced concentrations of the intact plasma kallikrein–HMW-
kininogen complex in circulation.
We observed that plasma kallikrein activity was lower in
individuals on dialysis compared with those who had received
a kidney transplant. As individuals on dialysis have the most
damage to their endothelium, lower plasma kallikrein activity
would be expected in these individuals than in the kidney
transplant recipients.
However, whether reduced plasma kallikrein activity is bene-
ficial or deleterious in diabetic nephropathy is unknown. It is
generally understood that the KKS has a protective effect under
physiological and pathophysiological conditions [12–14], and
plasma kallikrein has been associated with increased NO release
and fibrin degradation, which are functions relevant to vascular
Table 1 Plasma kallikrein activity associations
Chr. SNP Gene Trait EA EAF Plasma kallikrein
β (95% CI) p value
3 rs5030062 KNG1 Factor XI/Pre-kallikrein C 0.35 0.25 (0.11, 0.38) 3.9 × 10−4
3 rs710446 KNG1 Factor XI C 0.37 0.24 (0.11, 0.37) 3.5 × 10−4
4 rs1511802 KLKB1 Pre-kallikrein C 0.44 0.12 (−0.02, 0.25) 0.085
4 rs6842047 KLKB1 Factor XI A 0.09 −0.02 (−0.23, 0.18) 0.81
4 rs4253417 F11 Factor XI C 0.45 0.10 (−0.03, 0.23) 0.13
4 rs2289252 F11 Factor XI T 0.43 0.09 (−0.04, 0.21) 0.19
5 rs1801020 F12 Factor XII A 0.25 −0.63 (−0.77, −0.50) 3.2 × 10−17
Chr., chromosome; EA, effect allele (= minor allele); EAF, effect allele frequency; associations are adjusted for age, sex and diabetes duration. A
Bonferroni-corrected p value of <0.007 was considered statistically significant
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protection. Consistent with these findings,KNG1 rs5030062 and
rs710446, which are known to increase plasma pre-kallikrein
and/or FXI levels, associated with both plasma kallikrein activity
and with increased eGFR in this study.
Our study was subject to certain limitations. The number of
participants with available plasma samples was relatively
small and therefore the study was not powered to detect any
subtle changes that might exist. However, the observed effect
size of the association between plasma kallikrein activity and
eGFR was high enough to be able to detect a difference with
99% power. In addition, plasma kallikrein and FXI protein
levels were not quantified in this study.
In this study we show that lower plasma kallikrein activity
levels accompany more severe diabetic nephropathy and lower
eGFR and that a genetic variant known to result in a higher
plasma pre-kallikrein level is associated with higher eGFR. We
propose that plasma kallikrein might have a protective effect on
kidney function in type 1 diabetes, but prospective studies are
needed to evaluate whether individuals with lower plasma kalli-
krein activity have worse kidney disease outcomes.
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